利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.039 秒)

    Octahedral molecular sieve sorbents and catalysts
    6.
    发明授权
    Octahedral molecular sieve sorbents and catalysts 失效
    八面体分子筛吸附剂和催化剂

    公开(公告)号：US07700517B2

    公开(公告)日：2010-04-20

    申请号：US11347459

    申请日：2006-02-03

    申请人： Liyu Li ,  David L. King

    发明人： Liyu Li ,  David L. King

    IPC分类号： B01J23/34 ,  B01J23/50 ,  B01J20/06

    CPC分类号： B01D53/949 ,  B01D53/9422 ,  F01N3/021 ,  F01N3/0807 ,  F01N2570/04

    摘要： Octahedral molecular sieve sorbents and catalysts are disclosed, including silver hollandite and cryptomelane. These materials can be used, for example, to catalyze the oxidation of COx (e.g., CO), NOx (e.g., NO), hydrocarbons (e.g., C3H6) and/or sulfur-containing compounds. The disclosed materials also may be used to catalyze other reactions, such as the reduction of NO2. In some cases, the disclosed materials are capable of sorbing certain products from the reactions they catalyze. Silver hollandite, in particular, can be used to remove a substantial portion of certain sulfur-containing compounds from a gas or liquid by catalysis and/or sorption. The gas or liquid can be, for example, natural gas or a liquid hydrocarbon.

    摘要翻译： 公开了八面体分子筛吸附剂和催化剂，包括银胡萝卜素和cryptomelane。 这些材料可以用于例如催化COx（例如CO），NO x（例如NO），烃（例如C 3 H 6）和/或含硫化合物的氧化。 所公开的材料也可用于催化其它反应，例如还原NO 2。 在一些情况下，所公开的材料能够从它们催化的反应中吸收某些产物。 特别地，银矿砂可以用于通过催化和/或吸附从气体或液体中除去大部分某些含硫化合物。 气体或液体可以是例如天然气或液体烃。

    Sulfur oxide adsorbents and emissions control
    9.
    发明授权
    Sulfur oxide adsorbents and emissions control 失效
    硫氧化物吸附剂和排放控制

    公开(公告)号：US07153345B2

    公开(公告)日：2006-12-26

    申请号：US10771866

    申请日：2004-02-04

    申请人： Liyu Li ,  David L. King

    发明人： Liyu Li ,  David L. King

    IPC分类号： B01D53/50 ,  B01D53/56 ,  B01D53/94

    CPC分类号： B01D53/9431 ,  B01D53/949 ,  Y10S95/902

    摘要： High capacity sulfur oxide absorbents utilizing manganese-based octahedral molecular sieve (Mn—OMS) materials are disclosed. An emissions reduction system for a combustion exhaust includes a scrubber 24 containing these high capacity sulfur oxide absorbents located upstream from a NOX filter 26 or particulate trap.

    摘要翻译： 公开了使用锰基八面体分子筛（Mn​​-OMS）材料的高容量硫氧化物吸收剂。 用于燃烧排放的排放减少系统包括洗涤器24，洗涤器24包含位于NOX过滤器26或颗粒捕集器上游的这些高容量硫氧化物吸收剂。

    Simultaneous assay for determining drugs
    10.
    发明授权
    Simultaneous assay for determining drugs 有权
    用于确定药物的同时测定

    公开(公告)号：US07947465B2

    公开(公告)日：2011-05-24

    申请号：US12187661

    申请日：2008-08-07

    申请人： William F. Link ,  Renato B. del Rosario ,  Randy V. Sweet ,  David L. King

    发明人： William F. Link ,  Renato B. del Rosario ,  Randy V. Sweet ,  David L. King

    IPC分类号： G01N33/00

    CPC分类号： G01N33/54326 ,  G01N33/94 ,  G01N2446/00 ,  Y10T436/101666 ,  Y10T436/108331 ,  Y10T436/25125

    摘要： Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.

    摘要翻译： 在同时测定中分析体液中所选择的药物组的药物的存在，其中将流体样品与附加量的所有药物，面板每种药物特异的抗体和微粒 ，将微粒分为子集，面板中每种药物的一个子集，以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行，样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中，将所添加的药物预先偶联到微粒，而不是抗体，然后孵育后，用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中，所添加的药物不与微粒偶联，而是预先标记，而抗体预偶联于微粒，并且测定在不进一步孵育的情况下进行。 在两种替代方案中，微粒最终从测定培养基和任何未结合物质中回收，并且通过流式细胞术分析回收的微粒，以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ，每种药物通过微粒的区别特征与其他药物不同。